Statement of Retraction: Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study

International Journal of Psychiatry in Clinical Practice ◽

10.1080/13651501.2021.1950437 ◽

2021 ◽

pp. 1-1

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study

International Journal of Psychiatry in Clinical Practice ◽

10.1080/13651501.2017.1397700 ◽

2017 ◽

Vol 23 (4) ◽

pp. 245-250 ◽

Author(s):

Jing Wang ◽

Xi-Fang Liu ◽

Chong Feng ◽

Quan Bao ◽

Hong-Ran Fu

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Pharmacopsychiatry ◽

10.1055/s-2007-991684 ◽

2007 ◽

Vol 40 (05) ◽

Author(s):

M Ebrecht ◽

T Sickmann ◽

M Kungel ◽

C Werner ◽

R Marcus ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Adjunctive Therapy ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients

Neuropsychiatric Disease and Treatment ◽

10.2147/ndt.s48158 ◽

2013 ◽

pp. 1273 ◽

Author(s):

Yoshifumi Kobayashi ◽

Koshino ◽

Won-Myong Bahk ◽

Sakai

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Release Formulation ◽

Sustained Release Formulation ◽

Double Blind Placebo ◽

Download Full-text

Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study

Journal of Psychiatric Research ◽

10.1016/j.jpsychires.2020.05.017 ◽

2020 ◽

Vol 128 ◽

pp. 43-51

Author(s):

Makoto Kamiya ◽

Helene D. Sabia ◽

Julie Marella ◽

Maurizio Fava ◽

Charles B. Nemeroff ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Receptor Antagonist ◽

Adjunctive Treatment ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Vortioxetine in Adults With Major Depressive Disorder

The Journal of Clinical Psychiatry ◽

10.4088/jcp.14m09337 ◽

2015 ◽

Vol 76 (05) ◽

pp. 583-591 ◽

Author(s):

Atul R. Mahableshwarkar ◽

Paula L. Jacobsen ◽

Michael Serenko ◽

Yinzhong Chen ◽

Madhukar H. Trivedi

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Vortioxetine 10 mg and 20 mg in Adults With Major Depressive Disorder

The Journal of Clinical Psychiatry ◽

10.4088/jcp.14m09335 ◽

2015 ◽

Vol 76 (05) ◽

pp. 575-582 ◽

Author(s):

Paula L. Jacobsen ◽

Atul R. Mahableshwarkar ◽

Michael Serenko ◽

Serena Chan ◽

Madhukar H. Trivedi

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Desvenlafaxine Succinate in the Treatment of Major Depressive Disorder

The Journal of Clinical Psychiatry ◽

10.4088/jcp.v68n0504 ◽

2007 ◽

Vol 68 (05) ◽

pp. 677-688 ◽

Author(s):

Nicholas A. DeMartinis ◽

Paul P. Yeung ◽

Richard Entsuah ◽

Amy L. Manley

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Randomized, double‐blind, placebo‐controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder

Psychiatry and Clinical Neurosciences ◽

10.1111/pcn.12956 ◽

2019 ◽

Vol 74 (2) ◽

pp. 140-148 ◽

Author(s):

Takeshi Inoue ◽

Kiyofumi Sasai ◽

Tadayuki Kitagawa ◽

Akira Nishimura ◽

Isao Inada

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Japanese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan

Neuropsychiatric Disease and Treatment ◽

10.2147/ndt.s146428 ◽

2018 ◽

Vol Volume 14 ◽

pp. 1261-1272 ◽

Author(s):

Yoshinori Watanabe ◽

Yuko Asami ◽

Yoko Hirano ◽

Kazuhiko Kuribayashi ◽

Rio Itamura ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Extended Release ◽

Controlled Study ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

Subgroup Analyses ◽

Download Full-text

Reboxetine, placebo and paroxetine comparison in patients with major depressive disorder: A double-blind, placebo- and comparator-controlled study

European Neuropsychopharmacology ◽

10.1016/s0924-977x(01)80204-2 ◽

2001 ◽

Vol 11 ◽

pp. S216 ◽

Author(s):

C.C. Gallen ◽

M.T. Brown

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Controlled Study ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text